	PHARMA CODE N° 0306			
SmithKline RSC A/W Version:				
Jumber:				
000116742				
ncturing Site: 별 또 또 한				
or Pack Owner:				
rade Name:				
lours: 1				
e Varnish, if applicable)				
Tields provided below;     Image: Comparison of the second s		Combination with strong P-gp_inhibitors should be avoided, or selection of an alternate conco	omitant medication with	no or minimal potential to
Measur	<b>Votrient<sup>™</sup> 200 mg</b> film-coated tablets	inhibit P-gp is recommended. CYP3A4 Inducers: CYP3A4 inducers such as rifampin may decrease plasma pazopanib concentra medication with no or minimal enzyme induction potential is recommended.		
ent, THEN	Votrient™ 400 mg film-coated tablets Pazopanib	Effects of Pazopanib on CYP Substrates In vitro studies with human liver microsomes showed that pazopanib inhibited CYP enzymes 1A2	, 3A4, 2B6, 2C8, 2C9, 2C19	, and 2E1. Potential
Reference No(s).:	Qualitative and Quantitative Composition Votrient™ 200 mg: Each film-coated tablet contains 200 mg pazopanib (as hydrochloride). Votrient™ 400 mg: Each film-coated tablet contains 400 mg pazopanib (as hydrochloride).	induction of human CYP3A4 was demonstrated in an <i>in vitro</i> human PXR assay. Clinical pharmacc demonstrated that pazopanib does not have a clinically relevant effect on the pharmacokinetics probe substrate), or omeprazole (CYP2C19 probe substrate) in cancer patients. Pazopanib resulted	of caffeine (CYP1A2 probe d in an increase of approxi	e substrate), warfarin (CYP2) imately 30 % in the mean
widing a service to GSK for printed	See (List of excipients). Pharmaceutical form	AUC and C <sub>max</sub> of midazolam (CYP3A4 probe substrate) and increases of 33% to 64% in the ratio of the urine after oral administration of dextromethorphan (CYP2D6 probe substrate). Co-administr 80 mg/m <sup>2</sup> (CYP3A4 and CYP2C8 substrate) once weekly resulted in a mean increase of 26 % and 3	ration of pazopanib 800 m	g once daily and paclitaxel
any description must ensure that nce for all fonts / software used in ction with GSK artwork.	Votrient™ 200 mg: Capsule-shaped, pink, film-coated tablet with GS JT debossed on one side. Votrient™ 400 mg: Capsule-shaped, white, film-coated tablet with GS UHL debossed on one side. <b>Therapeutic indications</b>	Effects of Pazopanib on Other Enzymes and Transporters In vitro studies also showed that pazopanib is a potent inhibitor of UGT1A1 and OATP1B1 with increase concentrations of drugs primarily eliminated through UGT1A1 and OATP1B1.		
will not accept any liability for the arty intellectual property rights by d component suppliers. fication / audit process requires	Renal cell carcinoma (RCC) Votrient is indicated in adults for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.	Effect of concomitant use of Pazopanib and Simvastatin Concomitant use of pazopanib and simvastatin increases the incidence of ALT elevations. Across n		
e and may require the supplier to idence of such licence to GSK.	Soft tissue sarcoma (STS) Votrient is indicated for the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior	was reported in 126 / 895 (14 %) of patients who did not use statins, compared with11/41 (27 %) o (p = 0.038). If a patient receiving concomitant simvastatin develops ALT elevations, follow guidelin (see Warnings and Precautions). Insufficient data are available to assess the risk of concomitant ac	nes for pazopanib posolog	y and discontinue simvastat
DN • ATTENTION	chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy. Efficacy and safety has only been established in certain STS histological tumour subtypes. <b>Posology and method of administration</b>	Effect of Food on Pazopanib Administration of pazopanib with a high-fat or low-fat meal results in an approximately 2-fold should be administered at least 1 hour before or 2 hours after a meal (see Dosage and Administered)	l increase in AUC and C <sub>max</sub>	
VIEWING: Use Adobe Acrobat 5 dobe Acrobat Reader, Standard or gher than 5). Overprint Preview d for accurate on screen viewing.	Votrient treatment should only be initiated by a physician experienced in the administration of anti-cancer agents. Posology Adults	Pregnancy and Lactation Fertility		
G: Use only Acrobat Professional er. "Apply Overprint Preview" or printing" must be activated in the	The recommended dose of pazopanib for the treatment of RCC or STS is 800 mg once daily. <u>Dose modifications</u>	Pazopanib may impair fertility in human males and females. In female reproductive toxicity stud <b>Pregnancy</b> There are no adequate data from the use of pazopanib in pregnant women. Studies in animals		
or printing accurate hard copies.	Dose modification should be in 200 mg increments in a stepwise fashion based on individual tolerability in order to manage adverse reactions. The dose of pazopanib should not exceed 800 mg. <u>Paediatric population</u>	risk for humans is unknown. Pazopanib should not be used during pregnancy unless the clinica pazopanib. If pazopanib is used during pregnancy, or if the patient becomes pregnant while re	al condition of the womar	n requires treatment with
	Pazopanib should not be used in children younger than 2 years of age because of safety concerns on organ growth and maturation. The safety and efficacy of pazopanib in children aged 2 to 18 years of age have not yet been established. No data are available. <u>Elderly</u>	should be explained to the patient. Women of childbearing potential should be advised to use adequate contraception and avoid pazopanib.	becoming pregnant while	e receiving treatment with
ONT PAGE	There are limited data of the use of pazopanib in patients aged 65 years and older. In the RCC studies of pazopanib, overall no clinically significant differences in safety of pazopanib were observed between subjects aged at least 65 years and younger subjects. Clinical experience has not	Lactation The safe use of pazopanib during lactation has not been established. It is not known whether should be discontinued during treatment with pazopanib.	pazopanib is excreted in	human milk. Breast feeding
PE SIZE: 9/9.8	identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. <u>Renal impairment</u> Renal impairment is unlikely to have a clinically relevant effect on pazopanib pharmacokinetics given the low renal excretion of pazopanib and	Ability to perform tasks that require judgment, motor or cognitive skills There have been no studies to investigate the effect of pazopanib on driving performance or t	he ability to operate mac	hinery. A detrimental effe
NTAL SCALE: 90%	metabolites. Therefore, no dose adjustment is required in patients with creatinine clearance above 30 ml/min. Caution is advised in patients with creatinine clearance below 30 ml/min as there is no experience of pazopanib in this patient population. <u>Hepatic impairment</u>	on such activities would not be anticipated from the pharmacology of pazopanib. The clinical s pazopanib should be borne in mind when considering the patient's ability to perform task tha <b>Adverse Reactions</b>	t require judgment, moto	or and cognitive skills.
ORTANT	Dosing recommendations in hepatically impaired patients are based on pharmacokinetic studies of pazopanib in patients with varying degrees of hepatic dysfunction. Administration of pazopanib to patients with mild or moderate hepatic impairment should be undertaken with caution and	The safety and efficacy of pazopanib in renal cell carcinoma (RCC) were evaluated in a random study. Patients with locally advanced and/or metastatic RCC were randomized to receive pazop The median duration of treatment was 7.4 months for the pazopanib arm and 3.8 months for t	anib 800 mg once daily (I	
rket is responsible product, its design	close monitoring of tolerability. 800 mg pazopanib once daily is the recommended dose in patients with mild abnormalities in serum liver tests (defined as either normal bilirubin and any degree of alanine aminotransferase (ALT) elevation or as an elevation of bilirubin (> 35 % direct) up to 1.5 x upper limit of normal (ULN) regardless of the ALT value). A reduced pazopanib dose of 200 mg once daily is recommended in patients with	The safety and efficacy of pazopanib in soft tissue sarcoma (STS) were evaluated in a randomiz study. Patients (N = 369) with advanced STS who had received prior anthracycline treatment, o	zed, double-blind, placebo r were unsuited for such t	therapy, were randomized
nd content. e the artwork is nly checked, all the	moderate hepatic impairment (defined as an elevation of bilirubin > 1.5 to 3 x ULN regardless of the ALT values). Pazopanib is not recommended in patients with severe hepatic impairment (defined as total bilirubin > 3 X ULN regardless of any level of ALT). Method of administration	receive pazopanib 800 mg once daily (N = 246) or placebo (N = 123). The median duration of tr 1.9 months for the placebo arm. Adverse reactions are listed below by MedDRA body system organ class.	atment was 4.5 months	for the pazopanib arm and
-read and approved. s responsible for site	Pazopanib should be taken without food, at least one hour before or two hours after a meal. Votrient film-coated tablets should be taken whole with water and not broken or crushed.	The following convention has been utilised for the classification of frequency: Very common $\ge 1$ in 10 Common $\ge 1$ in 100 and < 1 in 10		
l requirements and press suitability.	Contraindications Hypersensitivity to the active substance or to any of the excipients. Warnings and Precautions	Uncommon $\geq$ 1 in 1,000 and < 1 in 100 Categories have been assigned based on absolute frequencies in the clinical trial data.		
SK Market sible to advise RSC	Hepatic Effects: Cases of hepatic failure (including fatalities) have been reported during use of pazopanib. In clinical trials with pazopanib, increase in serum transaminases (ALT, AST) and bilirubin were observed (see Adverse Reactions). In the majority of the cases, isolated increases in ALT and AST have been reported, without concomitant elevations of alkaline phosphatase or bilirubin. The vast majority (over 90 %) of all transaminase	Table 1 Adverse reactions, by organ class and frequency, reported in RCC (VEG105192) and ST		ncy classification
changes required t the followings:	elevations of any grade occurred in the first 18 weeks. Grades are based on the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3 (NCI CTCAE).		RCC VEG105192 n=2	STS 90 VEG110727 n=240
mulation t embossing	Monitor serum liver tests before initiation of treatment with pazopanib, and at weeks 3, 5, 7 and 9. Thereafter monitor at Month 3 and at Month 4, and as clinically indicated. Periodic monitoring should then continue after Month 4. The following guidelines are provided for patients with baseline values of total bilirubin $\leq$ 1.5 X ULN and AST and ALT $\leq$ 2 X ULN.	Blood and lymphatic system disorders Neutropenia Thrombocytopenia	Common	▲
e conditions nelf Life	<ul> <li>Patients with isolated ALT elevations between 3 X ULN and 8 X ULN may be continued on pazopanib with weekly monitoring of liver function until ALT return to Grade 1 (NCI CTCAE) or baseline.</li> <li>Patients with ALT of &gt; 8 X ULN should have pazopanib interrupted until they return to Grade 1 (NCI CTCAE) or baseline. If the potential benefit</li> </ul>	Endocrine disorders		
	for reinitiating pazopanib treatment is considered to outweigh the risk for hepatotoxicity, then reintroduce pazopanib at a reduced dose of 400 mg once daily and measure serum liver tests weekly for 8 weeks (see Dosage and Administration)]. Following reintroduction of pazopanib, if ALT elevations > 3 X ULN recur, then pazopanib should be permanently discontinued.	Hypothyroidism*  Metabolic and nutrition disorders	Common	Common
ge 1 of 2	<ul> <li>If ALT elevations &gt; 3 X ULN occur concurrently with bilirubin elevations &gt; 2 X ULN pazopanib should be permanently discontinued. Patients should be monitored until return to Grade 1 (NCI CTCAE) or baseline. Pazopanib is a UGT1A1 inhibitor. Mild, indirect (unconjugated)</li> </ul>	Anorexia Weight decreased	Very common Common	Very common Very common
	hyperbilirubinaemia may occur in patients with Gilbert's syndrome. Patient's with only a mild indirect hyperbilirubinaemia, known or suspected Gilbert's syndrome, and elevation in ALT > 3 X ULN should be managed as per the recommendations outlined for isolated ALT elevations. Concomitant use of pazopanib and simvastatin increases the risk of ALT elevations (see Interactions) and should be undertaken with caution and	Nervous system disorders Dizziness		Very common
	close monitoring. Beyond recommending that patients with mild hepatic impairment are treated with 800 mg pazopanib once daily and reducing the initial starting dose to 200 mg per day for patients with moderate impairment, no further dose modification guidelines based on results of serum liver tests during	Dysgeusia Headache	Common Very common	Very common Very common
	therapy have been established for patients with pre-existing hepatic impairment. Hypertension: In clinical studies with pazopanib, events of hypertension including hypertensive crisis have occurred. Blood pressure should be well controlled prior to initiating pazopanib. Patients should be monitored for hypertension early after starting treatment (no longer than	Ischaemic stroke* Transient ischaemic attack*	Uncommon Common	Uncommon
	one week after starting pazopanib) and frequently thereafter to ensure blood pressure control, and treated promptly with a combination of standard anti-hypertensive therapy and pazopanib dose reduction or interruption as clinically warranted (see Dosage and Administration, Adverse	Cardiac disorders Cardiac dysfunction (such as a decrease in ejection fraction and congestive heart failure)*	Uncommon	Common
	<i>Reactions</i> ). Hypertension (systolic blood pressure ≥ 150 or diastolic blood pressure ≥ 100 mm Hg) occurs early in the course of pazopanib treatment (approximately 40% of cases occurred by Day 9 and approximately 90% of cases occurred in the first 18 weeks). Pazopanib should be discontinued if there is evidence of hypertensive crisis or if hypertension is severe and persists despite anti-hypertensive therapy and pazopanib dose reduction.	Bradycardia (asymptomatic) <sup>†</sup> Myocardial infarction*	Very common Uncommon	Very common Common
	Posterior reversible encephalopathy syndrome (PRES) /Reversible posterior leukoencephalopathy syndrome (RPLS): PRES/RPLS has been reported in association with pazopanib. PRES/RPLS can present with headache, hypertension, seizure, lethargy, confusion, blindness and other visual and neurological disturbances, and can be fatal. Permanently discontinue pazopanib in patients developing PRES/RPLS.	Myocardial ischaemia QT prolongation*	Common Common	Common
	Cardiac Dysfunction: In clinical trials with pazopanib, events of cardiac dysfunction such as congestive heart failure and decreased left ventricular ejection fraction (LVEF) have occurred. Congestive heart failure was reported in 3 out of 240 subjects (1%) in the phase III STS clinical trial. In this	Torsade de Pointes* Vascular disorders	Uncommon	•
	trial decreases in LVEF in subjects who had post-baseline measurement were detected in 11 % (16/142) in the pazopanib arm compared with 5 % (2/40) in the placebo arm. Fourteen of the 16 subjects in the pazopanib arm had concurrent hypertension which may have exacerbated cardiac dysfunction in patients at risk (e.g., those with prior anthracycline therapy) by increasing cardiac after-load.	Cerebral haemorrhage* Epistaxis	Uncommon Common	Uncommon Common
	Blood pressure should be monitored and managed promptly using a combination of anti-hypertensive therapy and dose modification of pazopanib (interruption and re-initiation at a reduced dose based on clinical judgment). Patients should be carefully monitored for clinical signs or symptoms of congestive heart failure. Baseline and periodic evaluation of LVEF is recommended in patients at risk of cardiac dysfunction.	Gastrointestinal haemorrhage* Haematuria Hypertension*	Uncommon Common Very common	Uncommon Uncommon Very common
	<b>QT Prolongation and Torsade de Pointes:</b> In clinical studies with pazopanib, events of QT prolongation or Torsade de Pointes have occurred (see Adverse Reactions). Pazopanib should be used with caution in patients with a history of QT interval prolongation, patients taking	Pulmonary haemorrhage* Venous thromboembolic events*	Uncommon	Common Common
	antiarrythmics or other medications that may potentially prolong QT interval, or those with relevant pre-existing cardiac disease. When using pazopanib, baseline and periodic monitoring of electrocardiograms and maintenance of electrolytes (calcium, magnesium, potassium) within normal range is recommended.	Respiratory, thoracic and mediastinal disorders		
	Arterial Thrombotic Events: In clinical studies with pazopanib, myocardial infarctions, angina, ischemic stroke and transient ischemic attack were observed (see Adverse Reactions). Fatal events have been observed. Pazopanib should be used with caution in patients who are at increased risk of thrombotic events or who have had a history of thrombotic events. Pazopanib has not been studied in patients who have had an event within the	Cough Dysphonia Dyspnoea	Common	Very common Common Very common
	previous 6 months. A treatment decision should be made based upon the assessment of individual patient's benefit/risk. Venous Thromboembolic Events: In clinical studies with pazopanib, venous thromboembolic events including venous thrombosis and fatal	Pneumothorax	<b>♦</b>	Common
	pulmonary embolus have occurred. The incidence was higher in the STS population (5 %) than in the RCC population (2 %). Thrombotic Microangiopathy: Thrombotic microangiopathy (TMA) has been reported in clinical trials of pazopanib as monotherapy, in combination with bevacizumab, and in combination with topotecan (see Adverse Reactions). Permanently discontinue pazopanib in patients developing TMA.	Gastrointestinal disorders Abdominal pain	Very common	Very common
	Reversal of effects of TMA has been observed after treatment was discontinued. Pazopanib is not indicated for use in combination with other agents.	Diarrhoea Dyspepsia Gastrointestinal perforation*	Very common Common Uncommon	Common
	Haemorrhagic Events: In clinical studies with pazopanib haemorrhagic events have been reported (see Adverse Reactions). Fatal haemorrhagic events have occurred. Pazopanib has not been studied in patients who had a history of haemoptysis, cerebral, or clinically significant gastrointestinal haemorrhage in the past 6 months. Pazopanib should be used with caution in patients with significant risk of haemorrhage.	Gastrointestinal fistula* Lipase elevations	Uncommon Common	Uncommon
	Gastrointestinal Perforations and Fistula: In clinical studies with pazopanib, events of gastrointestinal (GI) perforation or fistula have occurred (see Adverse Reactions). Fatal perforation events have occurred. Pazopanib should be used with caution in patients at risk for GI perforation or fistula. Wound Healing: No formal studies on the effect of pazopanib on wound healing have been conducted. Since Vascular Endothelial Growth Factor	Nausea Stomatitis	Very common	Very common Very common Very common
	(VEGF) inhibitors may impair wound healing, treatment with pazopanib should be stopped at least 7 days prior to scheduled surgery. The decision to resume pazopanib after surgery should be based on clinical judgement of adequate wound healing. Pazopanib should be discontinued in	Vomiting Hepatobiliary disorders	Very common	Very common
	patients with wound dehiscence. Hypothyroidism: In clinical studies with pazopanib, events of hypothyroidism have occurred (see Adverse Reactions). Proactive monitoring of thyroid function tests is recommended.	Alanine aminotransferase increased Aspartate aminotransferase increased	Very common Very common	Common Common
	Proteinuria: In clinical studies with pazopanib, proteinuria has been reported (see Adverse Reactions). Baseline and periodic urinanlyses during treatment are recommended and patients should be monitored for worsening proteinuria. Pazopanib should be discontinued if the patient develops nephrotic syndrome.	Hepatic function abnormal Hyperbilirubinaemia	Common Common	◆ Uncommon
	Infections: Cases of serious infections (with or without neutropenia), in some cases with fatal outcome, have been reported. Combination with other systemic anti-cancer therapies: Clinical trials of pazopanib in combination with pemetrexed (non-small cell lung cancer	Skin and subcutaneous tissue disorders Alopecia	Common	Very common
	(NSCLC)) and lapatinib (cervical cancer) were terminated early due to concerns over increased toxicity and/or mortality, and a safe and effective combination dose has not been established with these regimens. Pazopanib is not indicated for use in combination with other agents. Juvenile animal toxicity: Because the mechanism of action of pazopanib can severely affect organ growth and maturation during early post-natal	Dry skin Exfoliative rash	* *	Common Very common
	development (see Non-clinical Information), pazopanib should not be given to human paediatric patients younger than 2 years of age. Pregnancy: Pre-clinical studies in animals have shown reproductive toxicity.	Hair depigmentation Nail disorder Palmar-plantar erythrodysaesthesia syndrome	Very common   Common	Very common Common
	If pazopanib is used during pregnancy, or if the patient becomes pregnant while receiving pazopanib, the potential hazard to the foetus should be explained to the patient. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with pazopanib (see Pregnancy and Lactation).	Palmar-plantar erythrodysaesthesia syndrome Rash Skin depigmentation	Common Common Common	Very common Uncommon Very common
	Interactions; Concomitant treatment with strong inhibitors of CYP3A4 or P-glycoprotein (P-gp) should be avoided due to risk of increased exposure to pazopanib (see Interactions). Selection of alternative concomitant medicinal products with no or minimal potential to inhibit CYP3A4 or P-gp should be considered. Interactions	Musculoskeletal and connective tissue disorders Musculoskeletal pain	• •	Very common
	Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes In vitro studies suggested that the oxidative metabolism of pazopanib in human liver microsomes is mediated primarily by CYP3A4, with minor contributions from CYP1A2 and CYP2C8. Therefore, inhibitors and inducers of CYP3A4 may alter the metabolism of pazopanib.	Myalgia Renal and urinary disorders	▲	Very common
	CYP3A4, P-gp, Breast Cancer Resistance Protein (BCRP) Inhibitors: Pazopanib is a substrate for CYP3A4, P-gp and BCRP Concurrent administration of pazopanib (400 mg once daily) with the strong CYP3A4 and P-gp inhibitor, ketoconazole (400 mg once daily) for 5	Proteinuria*	Common	Uncommon
	consecutive days, resulted in a 66 % and 45 % increase in mean pazopanib AUC <sub>(0-24)</sub> and C <sub>max</sub> , respectively, relative to administration of pazopanib alone (400 mg once daily for 7 days). Pazopanib C <sub>max</sub> and AUC increase in a less than dose proportional fashion with increasing dose over the range of 50 mg to 2000 mg. Therefore, a dose reduction to 400 mg pazopanib once daily in the presence of strong CYP3A4 inhibitors will, in the majority	General disorders and administration site disorders Asthenia Cheat paint	Very common	Uncommon
	of patients, result in systemic exposure similar to that observed after administration of 800 mg pazopanib once daily alone. Some patients however may have systemic pazopanib exposure greater than what has been observed after administration of 800 mg pazopanib alone.	Chest pain* Chills Fatigue	Common  Very common	Very common Common Very common
	Co-administration of pazopanib with other strong inhibitors of the CYP3A4 family (e.g., itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase pazopanib concentrations. Grapefruit juice may also increase plasma concentrations of pazopanib.	Oedema peripheral Vision blurred		Very common Very common Common
	Administration of 1500 mg lapatinib a substrate and weak inhibitor of CYP3A4, Pgp and BCRP with 800 mg pazopanib resulted in an approximately $50\%$ to $60\%$ increase in mean pazopanib AUC are and C compared to administration of 800 mg pazopanib alone. Co-administration of	* See Warnings and Precautions for additional information.		

Administration of 1500 mg lapatinib a substrate and weak inhibitor of CYP3A4, Pgp and BCRP with 800 mg pazopanib resulted in an approximately 50 % to 60 % increase in mean pazopanib AUC<sub>(0-24)</sub> and C<sub>max</sub> compared to administration of 800 mg pazopanib alone. Co-administration of pazopanib with a CYP3A4, Pgp, and BCRP inhibitor, such as lapatinib, will result in an increase in plasma pazopanib concentrations. Concomitant use of pazopanib with a strong CYP3A4 inhibitor should be avoided. If no medically acceptable alternative to a strong CYP34A inhibitor is available, the dose of pazopanib should be reduced to 400 mg daily during concomitant administration (see Warnings and Precautions). Further dose reduction may be considered if possible drug-related adverse events are observed.

\* See Warnings and Precautions for additional information.
 - Adverse event was not considered causally related to pazopanib in the pivotal clinical trial for this indication.
 Note: Laboratory findings which met the CTC-AE criteria were recorded as adverse events at the discretion of the Investigator

 - Frequency based on heart rate measurement (< 60 beats per minute) rather than adverse event reports. Symptomatic bradycardia has been identified rarely based on a review of the pazopanib safety database.</li>
 + For RCC, the frequency category is based on data from the supportive single-arm study VEG102616.

#### 10000000116742

# This PDF has been verified using PitStop 08 - PDF is PDF/X-1a compliant (InDesign files workflow)

Artworl Panel	( Informatio	on	Version: 1			
ltem Nu 1000000	mber: 00116742					
	cturing Site: P-Aranda-ES		A			
	Market or Pack Owner: Gulf and Near East-GNE					
Market <sup>-</sup> Votrient	Trade Name	:				
	olours: 1 ude Varnish, if applic	able)				
	<b>DUTS:</b> e in fields provided b t-CMYK equivalent)	elow;		ן ו		
К						
			-i	1		

GlaxoSmithKline

RSC A/W

Technical Reference No(s).: 02-01-XX-273-15 Artwork copyright is the property of the GlaxoSmithKline Group of Companies All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts / software used in conjunction with GSK artwork. The distribution and use of fonts / software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by

print party intellectual property infines by printed component suppliers. The GSK certification / audit process requires suppliers to declare that they do not use unlicensed fonts / software and may require the supplier to produce evidence of such licence to GSK.

ATTENTION • ATTENTION To Ensure Accurate PDF Viewing and Printing: FOR SCREEN VIEWING: Use Adobe Acrobat 5 ofessional or Adobe Acrobat Reader, Standard o Professional (higher than 5). **Overprint Preview** must be activated for accurate on screen viewing. FOR PRINTING: Use only Acrobat Professional sion 5 or higher. "Apply Overprint Preview" o "Simulate Overprinting" must be activated in the print settings for printing accurate hard copies.

## **BACK PAGE**

**TYPE SIZE: 9/9.8 HORIZONTAL SCALE: 90%** 

## IMPORTANT

**GSK Market is responsible** for this product, its design and content. Ensure the artwork is thoroughly checked, all the text proof-read and approved

**RSC GSK is responsible for site** technical requirements and pre-press suitability.

GSK Market responsible to advise RSC in case changes required impact the followings:

Table 2 presents laboratory abnormalities occurring in  $\geq$  15 % of patients who received pazopanib in the pivotal RCC studies. Grades are based on the NCI CTCAE Table 2 Selected Laboratory Abnormalities in ≥ 15 % of Patients who Received Pazopanib and More Commonly than Placebo Arm (VEG105192)

	Pazopanib (N = 290)			Placebo (N = 145)		
	All Grades	Grade 3 %	Grade 4 %	All Grades	Grade 3	Grade 4 %
Parameters	%			%	%	
Haematological						
Leukopenia	37	0	0	6	0	0
Neutropenia	34	1	<1	6	0	0
Thrombocytopenia	32	<1	<1	5	0	<1
Lymphocytopenia	31	4	<1	24	1	0
Chemistry						
ALT increased	53	10	2	22	1	0
AST increased	53	7	<1	19	<1	0
Glucose increased	41	<1	0	33	1	0
Total Bilirubin increased	36	3	<1	10	1	<1
Phosphorus decreased	34	4	0	11	0	0
Calcium decreased	33	1	1	26	1	<1
Sodium decreased	31	4	1	24	4	1
Potassium increased	27	4	<1	23	5	0
Creatinine increased	26	0	<1	25	<1	0
Magnesium decreased	26	<1	1	14	0	0
Glucose decreased	17	0	<1	3	0	0

Table3 presents laboratory abnormalities occurring in  $\geq$  15 % of patients who received pazopanib in the pivotal STS study. Grades are based on the NCI CTCAE

Table 3 Selected Laboratory Abnormal	ities in ≥ 15 % of Patients who Receiv	ved Pazopanib and More Con	nmon than Placebo Arm (VEG110727)

	Pazopanib (N = 240)			Placebo (N = 123)			
	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4	
Parameters	%	%	%	%	%	%	
Haematological							
Leukopenia	44	1	0	15	0	0	
Neutropenia	33	4	0	7	0	0	
Thrombocytopenia	36	3	<1	6	0	0	
Lymphocytopenia	43	10	0	36	9	2	
Anaemia	27	5	2	23	<1	<1	
Chemistry							
ALKP increased	32	3	0	23	<1	0	
ALT increased	46	8	2	18	2	<1	
AST increased	51	5	3	22	2	0	
Albumin increased	34	<1	0	21	0	0	
Glucose increased	45	<1	0	35	2	0	
Total Bilirubin increased	29	1	0	7	2	0	
Sodium decreased	31	4	0	20	3	0	
Potassium increased	16	1	0	11	0	0	

The following adverse reactions have been identified during post-approval use of pazopanib. This includes spontaneous case reports as well as serious adverse events from ongoing studies, clinical pharmacology studies and exploratory studies in unapproved indications. Infections and infestations

Infections (with or without neutropenia) Uncommon Blood and lymphatic system disorders

Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome) Rare Nervous system disorders

Rare Posterior reversible encephalopathy syndrome Sixty-six percent of placebo patients received post-study therapy compared to 30 % of pazopanib patients.

In the pivotal study, the QoL assessments were based on blinded self-reported global scores from two protocol-specified questionnaires, EORTC QLQ-C30 and EuroQoL EQ-5D. Analysis was based on patients who continued on therapy in both arms, prior to progression. The assessments showed no difference between treatment with pazopanib or placebo (p > 0.05), indicating no negative impact of pazopanib on global quality of life

In a Phase 2 study of 225 patients with locally recurrent or metastatic clear cell renal cell carcinoma, objective response rate was 35 % and median duration of response was 68 weeks, as per independent review.

#### Soft tissue sarcoma (STS)

The safety and efficacy of pazopanib in STS were evaluated in a randomized, double-blind, placebo-controlled multi-centre study. Patients (N=369) with advanced STS who had received prior chemotherapy, including anthracycline treatment, or were unsuited for such therapy, were randomized to receive pazopanib 800 mg once daily or placebo.

Prior to randomization, eligible subjects were stratified by the factors of WHO performance status (WHO PS) (0 or 1) at baseline and the number of lines of prior systemic therapy for advanced disease (0 or 1 vs. 2+). In each treatment group, there were a slightly greater percentage of subjects in the 2+ lines of prior systemic therapy for advanced disease (58 % and 55 % respectively for placebo and pazopanib treatment arms) compared with 0 or 1 lines of prior systemic therapy (42 % and 45 % respectively for placebo and pazopanib treatment arms). There were slightly more subjects with a WHO PS of 1 at baseline. The median duration of follow-up of subjects (defined as date of randomization to date of last contact or death) was similar for both treatment arms (9.36 months for placebo [range 0.69 to 23.0 months] and 10.04 months for pazopanib [range 0.2 to 24.3 months]

The primary objective of the study was to evaluate and compare the two treatment arms for progression-free survival (PFS), based on the ITT population, and the principle secondary endpoint is overall survival (OS).

The initial analysis of the primary endpoint PFS was based on disease assessment by independent radiological review in the entire ITT study population.

#### Table 5: Overall efficacy results in STS by independent assessment (VEG110727)

Endpoints/Study Population	Pazopanib	Placebo	HR (95% CI)	P value (one-sided)
PFS	· ·			
Overall* ITT	N = 246	N = 123		
Median (weeks)	20.0	7.0	0.35 (0.26, 0.48)	< 0.001
Response Rate (CR + PR)				
% (95 % CI)	4 (2.3, 7.9)	0 (0.0, 3.0)	-	-
Duration of response				-
Median (weeks) (95 % Cl))	38.9 (16.7, 40.0)	-	-	-
PFS				
Leiomyosarcoma	N = 109	N = 49		
Median (weeks)	20.1	8.1	0.37 (0.23, 0.60)	< 0.001
Synovial sarcoma	N = 25	N = 13		
Median (weeks)	17.9	4.1	0.43 (0.19, 0.98)	0.005
'Other' STS	N = 112	N = 61		
Median (weeks)	20.1	4.3	0.39 (0.25, 0.60)	< 0.001

HR = Hazard ratio; ITT = Intent to treat; PFS = Progression-free survival; CR = Complete Response; PR = Partial Response. Similar to the assessments by independent radiology review, a clinically meaningful and statistically significant improvement in PFS based on investigator assessments was observed in the pazopanib arm compared with the placebo arm (HR: 0.39; 95 % CI, 0.30 to 0.52, p < 0.001). The hazard ratio at the pre-specified interim analysis for overall survival in favour of pazopanib was not statistically significant; the median overall survival in the placebo arm was 10.4 months (95 % CI 8.7 to 12.7) and was 11.9 months (95 % CI 10.7 to 15.1) in the pazopanib arm; HR = 0.82 (97.87 % CI: 0.59 to 1.14, p = 0.156).

Non-Clinical information

Carcinogenesis, Mutagenesis, Impairment of Fertility

Although definitive carcinogenicity studies with pazopanib have not been performed, mice given 1,000 mg/kg/day (approximately 1.5 times the human clinical exposure based on AUC) for 13 weeks had proliferative lesions noted in the liver including eosinophilic foci in 2 females and a single case of adenoma in another female.

Pazopanib did not cause genetic damage when tested in genotoxicity assays (Ames assay, human peripheral lymphocyte chromosome aberration assay, and rat in vivo micronucleus assay).

In female rats, reduced fertility including increased pre- and post-implantation loss, early resorptions, were noted at

dosages  $\geq$  10 mg/kg/day (approximately 0.2 times the human clinical exposure based on AUC). Decreased corpora lutea were noted in monkeys given 500 mg/kg/day for up to 34 weeks, in mice given ≥ 100 mg/kg/day for 13 weeks and ovarian atrophy was noted in rats given 300 mg/kg/day for 26 weeks (approximately equal to, 0.6, 1.4 and 0.9 times the human clinical exposure based on AUC, respectively).

Pazopanib did not affect mating or fertility in male rats. However, there were reductions in sperm production rates, sperm motility, and epididymal and testicular sperm concentrations observed at  $\geq$  100 mg/kg/day (approximately 0.5 times the human clinical exposure based on AUC) following 15 weeks of dosing. Following 26 weeks of dosing, there were decreased testicular and epididymal weights, atrophy and degeneration of the testes with aspermia, hypospermia and cribiform change in the epididymis of male rats given doses ≥ 30 mg/kg/day (approximately 0.4 times the human clinical exposure based on AUC). Pazopanib produced foetal teratogenic effects (including cardiovascular malformations and delayed ossification), reduced foetal body weight, and embryo lethality in rats at a dose level of  $\geq$  3 mg/kg/day (approximately 0.1 times the human clinical exposure based on AUC). In rabbits, maternal toxicity (body weight loss, reduced food consumption, and abortion) were observed at doses  $\geq$  30 mg/kg/day (approximately 0.007 times the human clinical exposure based on AUC), while foetal weight was reduced at doses  $\geq$  3 mg/kg/day. (see Pregnancy and Lactation, Warnings and Precautions). Animal Toxicology and/or Pharmacology In toxicology studies in rats, there were effects in a variety of tissues (bone, teeth, bone marrow, nail beds, reproductive organs, haematological tissues, kidney, adrenal glands, lymph node, pituitary, and pancreas) consistent with VEGFR inhibition and/or disruption of VEGF signalling pathways with some effects occurring at doses of 3 mg/kg/day (approximately 0.1 times the human clinical exposure based on AUC). Hepatic effects included mild elevations of liver transaminases in rodents and bilirubin elevations in monkeys without associated histopathology at doses that produced systemic exposures approximately 0.1 and 0.6 times the human clinical exposure, respectively. In juvenile toxicity studies, when pre-weaning rats were dosed from day 9 post partum through day 14 postpartum, pazopanib caused mortalities and abnormal organ growth/maturation in kidney, lung, liver and heart, at a dose approximately 0.1 times the clinical exposure based on AUC in adults. When post weaning rats were dosed from day 21 post partum to day 62 post partum, toxicologic findings were similar to adult rats at comparable exposures with changes in bone, trachea, teeth, adrenal, pancreas, stomach, duodenum, lymph node, male mammary gland and reproductive organs. In rats, weaning occurs at day 21 postpartum which approximately equates to a human paediatric age of 2 years. Human pediatric patients are at increased risk for bone and teeth effects as compared to adults, as these changes, including shortened limbs, were present in juvenile rats at  $\geq$  10 mg/kg/day (equal to approximately 0.1-0.2 times the clinical exposure based on AUC in adults) (see Warnings and Precautions). List of excipients Tablet Core – 200 mg and 400 mg Magnesium stearate Microcrystalline cellulose Povidone (K30) Sodium starch glycollate Tablet film-coat - 200 mg (Opadry Pink) Hypromellose Iron Oxide Red (E172) Macrogol / PEG 400 Polysorbate 80 Titanium dioxide (E171) Tablet film-coat 400 mg (Opadry White) Hypromellose Macrogol / PEG 400 Polysorbate 80 Titanium dioxide (E171) Shelf life As indicated on the outer packaging. Special precautions for storage Store below 30°C. Nature and contents of container 200 mg tablet - High-density polyethylene (HDPE) bottles with child resistant polypropylene closures containing 30 or 90 tablets. 400 mg tablet - High-density polyethylene (HDPE) bottles with child resistant polypropylene closures containing 30 or 60 tablets. Not all pack sizes may be marketed. GDS Version Number: 09, Version Date: 21 December 2012 Manufactured by: Glaxo Operations UK Limited\*, Ware,UK Packed by : Glaxo Wellcome S.A.\*, Aranda de Duero, Spain \*Member of the GlaxoSmithKline group of companies. Votrient is a trademark of the GlaxoSmithKline group of companies. © 2011 GlaxoSmithKline group of companies. All rights reserved. THIS IS A MEDICAMENT Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you. Follow strictly the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medicament. - The doctor and the pharmacist are the experts in medicines, their benefits and risks. - Do not by yourself interrupt the period of treatment prescribed. - Do not repeat the same prescription without consulting your doctor. - Keep all medicaments out of the reach of children. Council of Arab Health Ministers, Union of Arab Pharmacists.

Formulation Tablet embossing Storage conditions Shelf Life

Page 2 of 2

Gastrointestinal disorders Uncommon Pancreatitis Hepatobiliary disorders Gamma-glutamyl transpeptidase increased Common Musculoskeletal and connective tissue disorders Arthralgia Verv common Overdosage Pazopanib doses up to 2,000 mg have been evaluated in clinical trials. Grade 3 fatigue (dose limiting toxicity) and Grade 3 hypertension were each observed in 1 of 3 patients dosed at 2,000 mg and 1,000 mg daily, respectively. Symptoms and Signs There is currently limited experience with overdosage in pazopanib. Treatment Further management should be as clinically indicated or as recommended by the national poisons centre, where available. Haemodialysis is not expected to enhance the elimination of pazopanib because pazopanib is not significantly renally excreted and is highly bound to plasma proteins. Clinical Pharmacology Pharmacodynamics ATC Code Pharmacotherapeutic group: Antineoplastic agents - Protein kinase inhibitor, ATC Code: L01XE11. Mechanism of Action Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor (TKI) of Vascular Endothelial Growth Factor Receptors (VEGFR)-1, -2, and -3, platelet-derived growth factor (PDGFR)- $\alpha$  and  $-\beta$ , and stem cell factor receptor (c-KIT), with IC<sub>50</sub> values of 10, 30, 47, 71, 84 and 74 nM, respectively. In preclinical experiments, pazopanib dose-dependently inhibited ligand-induced auto-phosphorylation of VEGFR-2, c-Kit and PDGFR-β receptors in cells. In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in various animal models, and the growth of multiple human tumour xenografts in mice. Pharmacokinetics Absorption Pazopanib is absorbed orally with median time to achieve peak concentrations of 2.0 to 4.0 hours after the dose. Daily dosing results in 1.23- to 4-fold increase in AUC. There was no consistent increase in AUC and C<sub>max</sub> when the pazopanib dose increased above 800 mg. Systemic exposure to pazopanib is increased when administered with food. Administration of pazopanib with a high-fat or low-fat meal results in an approximately 2-fold increase in AUC and C<sub>max</sub>. Therefore, pazopanib should be administered at least 1 hour before or 2 hours after a meal. Administration of a single pazopanib 400 mg crushed tablet increased AUC<sub>(0-72)</sub> by 46% and C<sub>max</sub> by approximately 2 fold and decreased t<sub>max</sub> by approximately 1.5 hours compared to administration of the whole tablet. These results indicate that the bioavailability and the rate of pazopanib oral absorption are increased after administration of the crushed tablet relative to administration of the whole tablet. Therefore, due to this potential for increased exposure, tablets should not be crushed. Distribution Binding of pazopanib to human plasma protein in vivo was greater than 99 % with no concentration dependence over the range of 10-100 µg/ml. In vitro studies suggest that pazopanib is a substrate for P-glycoprotein (Pgp) and breast cancer resistant protein (BCRP). Metabolism Results from in vitro studies demonstrated that the metabolism of pazopanib is mediated primarily by CYP3A4, with minor contributions from CYP1A2 and CYP2C8. Elimination Pazopanib is eliminated slowly with mean half-life of 30.9 hours after administration of the recommended dose of 800 mg. Elimination is primarily via faeces with renal elimination accounting for < 4 % of the administered dose. Special Populations Renal Impairment In a population pharmacokinetic analysis using 408 subjects with various cancers, creatinine clearance (30-150 ml/min) did not influence clearance of pazopanib. Renal impairment is not expected to influence pazopanib exposure, and dose adjustment is not necessary in patients with creatine clearance > 30 ml/min Hepatic Impairment The median steady-state pazopanib C<sub>max</sub> and AUC<sub>(0-24</sub>) in patients with mild hepatic impairment (defined as either normal bilirubin and any degree of ALT elevations or as an elevation of bilirubin up to 1.5 x ULN regardless of the ALT value) after a once daily dose of 800 mg/day (30.9 µg/ml, range 12.5-47.3 and 841.8 µg.hr/ml, range 600.4-1078) are similar to the median in patients with no hepatic impairment (49.4 µg/ml, range 17.1-85.7 and 888.2 µg.hr/ml, range 345.5-1482) (see Dosage and Administration). The maximally tolerated pazopanib dose (MTD) in patients with moderate hepatic impairment (defined as an elevation of bilirubin > 1.5 x to 3 x ULN regardless of the ALT values) was 200 mg once daily. The median steady-state values of C<sub>max</sub> (22.4 µg/ml, range 6.4-32.9) and AUC(0-24) (350.0 µg.hr/ml, range 131.8-487.7) after administration of 200 mg pazopanib once daily in subjects with moderate hepatic impairment were approximately 45 % and 39 %, respectively, that of the corresponding median values after administration of 800 mg once daily in subjects with normal hepatic function (see Dosage and Administration). There are insufficient data in patients with severe hepatic impairment (total bilirubin > 3 x ULN regardless of any level of ALT); therefore, use of pazopanib is not recommended in these patients. **Clinical Studies** Renal Cell Carcinoma (RCC) The safety and efficacy of pazopanib in renal cell carcinoma (RCC) were evaluated in a randomized, double-blind, placebo-controlled multi-centre study. Patients (N= 435) with locally advanced and/or metastatic RCC were randomized to receive pazopanib 800 mg once daily or placebo. The primary objective of the study was to evaluate and compare the two treatment arms for progression-free survival (PFS) and the principle secondary endpoint is overall survival (OS). The other objectives were to evaluate the overall response rate and duration of response. From the total of 435 patients in this study, 233 patients were treatment naïve and 202 were second line patients who received one prior IL-2 or INFg-based therapy. The performance status (ECOG) was similar between the pazopanib and placebo groups (ECOG 0: 42 % vs. 41 %, ECOG 1: 58 % vs. 59 %). All patients had clear cell histology or predominantly clear cell histology. Approximately half of all patients had 3 or more organs involved in their disease and most patients had the lung (74 %), and/or lymph nodes (54 %) as a metastatic location for disease at baseline. A similar proportion of patients in each arm were treatment-naïve and cytokine-pre-treated (53 % and 47 % in pazopanib arm, 54 % and 46 % in placebo arm). In the cytokine-pre-treated subgroup, the majority (75 %) had received interferon based treatment. Similar proportions of patients in each arm had prior nephrectomy (89 % and 88 % in the pazopanib and placebo arms, respectively) and/or prior radiotherapy (22 % and 15 % in the pazopanib and placebo arms, respectively. The primary analysis of the primary endpoint PFS is based on disease assessment by independent radiological review in the entire study population (first line and second line). Table 4. Overall Efficacy Results by Independent Review Committee (IRC) Endpoints/ Study population Pazopanib Placebo HR (95% CI) P value (one-sided) PFS Median (months) N=290 N=145 Overall 0.46 (0.34, 0.62) 9.2 4.2 < 0.000001 N=155 N=78 Treatment-naïve 11.1 2.8 < 0.000001 0.40 (0.27, 0.60)

مجلس وزراء الصحة العرب


و اتحاد الصيادلة العرب

### ان هذا الدواء

· الدواء مستحضر يؤثر على صحتك و استهلاكه خلافا للتعليمات يعرضك للخطر. - اتبع بدقة وصفة الطبيب و طريقة الاستعمال المنصوص عليها و تعليمات الصيدلاني الذي صرفها لك. - فالطبيب و الصيدلاني هما الخبيران بالدواء و بنفعه و ضرره. - لا تقطع مدة العلاج المحددة لك من تلقاء نفسك. - لا تكرر صرف الدواء بدون وصغة طبية.

لا تترك الأدوية في متناول أيدى الأطفال





N=67

N=145

4.2

% (95% CI)

N=135

N=290

7.4

Cytokine pre-treated

Response rate

Overall

[HR = 0.91 (95 % CI: 0.71, 1.16; p = 0.224)] for patients randomized to the pazopanib and placebo arms, respectively. The OS results are subject to potential bias as 54 % of patients in the placebo arm also received pazopanib in the extension part of this study following disease progression.

1000000116742

#### This PDF has been verified using PitStop 08 - PDF is PDF/X-1a compliant (InDesign files workflow)

< 0.001

0.54 (0.35, 0.84)